Loading stock data…
CTEV
$28.35+1.28 (+4.73%)
After Hours$28.40+0.05 (+0.18%)· Last close Jun 9
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
CTEV in the Healthcare sector is trading at $28.35. Wall Street consensus targets $36.83 (6 analysts), implying a +29.9% move over the next 12 months. The stock is currently 62% below its 52-week high of $74.07, remaining 23.2% below its 200-day moving average. On fundamentals, Piotroski 5/9 shows mixed financial quality, Altman Z in the distress zone. Risk note: RSI 76 is overbought against a weak tape. The Whystock Score of 60/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +29.9% upside over 12 months
Long-term trend bearish (price vs 200-day SMA)
Overbought RSI 76 against a weak tape — risk of pullback
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Anchored to each ticker's own 5-year median trailing P/E, tilted by current ROE and growth. Fair P/E = own median P/E + (ROE × 10) + (max(revenue growth, earnings growth) × 15), capped at ±30% around the historical anchor. Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. Premium compounders like COST/MSFT are judged against their own multi-year norm rather than a sector median. Falls back to the sector-anchored formula (Tech ≈ 28, Comm Services ≈ 24, Utilities ≈ 18, Financials ≈ 14, etc.) for recent IPOs and tickers with insufficient history (< 24 monthly samples). Result is a normalised multiple gauge — not a price target.
Current Price$28.35
Potential Downside
0%
Whystock Fair Value$28.35
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus6 analysts
Buy
Mean target$36.83+29.9%
Range$22.00 – $61.00
Fundamentals
Claritev Corporation, together with its subsidiaries, provides data analytics and technology-enabled end-to-end cost management, payment, and revenue integrity solutions to the healthcare industry in the United States. The company offers claims intel...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
-
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
-
Beta
High-beta play. Expect amplified moves vs. the broad market.
-
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
118.82%
Volume
Today's trading volume
67,432
Recent News
Sector Update: Healthcare Stocks Advance Late Afternoon
Healthcare stocks rose late Monday afternoon, with the NYSE Healthcare Index and the State Street He
Sector Update: Healthcare Stocks Advance Monday Afternoon
Healthcare stocks rose Monday afternoon, with the NYSE Healthcare Index adding 0.4% and the State St
Claritev Q1 Earnings Call Highlights
Claritev (NYSE:CTEV) reported first-quarter 2026 revenue and adjusted EBITDA ahead of internal expectations, while management said sales momentum and new-market expansion support its full-year outlook. President and CEO Travis Dalton said the quarter reflected “not just performance, but progress,”
Claritev Corporation Q1 2026 Earnings Call Summary
Moby summary of Claritev Corporation's Q1 2026 earnings call
Claritev Corporation (CTEV) Reports Q1 Loss, Tops Revenue Estimates
Claritev Corporation (CTEV) delivered earnings and revenue surprises of -15.75% and +3.30%, respectively, for the quarter ended March 2026. Do the numbers hold clues to what lies ahead for the stock?